New cancer drug NEV801 enters first human trials
NCT ID NCT02797795
First seen May 14, 2026 · Last updated May 14, 2026
Summary
This early-stage trial tested a new drug, NEV801, in 78 adults with advanced solid tumors who had no other treatment options. The main goal was to find the safest dose and check for side effects. Researchers also looked for any signs that the drug might shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Facility
Boston, Massachusetts, 02215, United States
-
Research Facility
Nashville, Tennessee, 37203, United States
Conditions
Explore the condition pages connected to this study.